06/01/2023at 15:41

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix

Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

EU Commission to give more time for MDR transition

A proposal meant to mitigate potential medical device shortages under the Medical Device Regulation is now headed to the European Parliament and Council under an accelerated procedure.

For subscribers

Pharma & biotech

Orifarm brings in communications lead from Leo Pharma

After around five years at Leo Pharma, Kristian Lysgaard is switching jobs to spearhead the communications team at Danish pharmaceutical firm Orifarm.

For subscribers

Pharma & biotech

Extensive layoffs at Leo Pharma – 300 jobs lost

On Thursday, Leo Pharma executed a firing round among employees primarily at the company’s R&D division.

For subscribers

Latest news

See all

Jobs

Head of Regulatory Affairs Danmark

See all jobs

Jobs

See all jobs

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Top news from MedWatch this week

Monday

Tuesday

Wednesday

Thursday

Friday

Sign up for our newsletter

Front page now

Novo Nordisk sues Viatris over copycat Wegovy

Novartis beats Kesimpta sales expectations in Q4

Analyst: Strong Novo Nordisk outlook should satisfy investors

Studies of Wegovy in higher-than-approved doses begin

Rare Disease business comes in slightly below expectations for Novo Nordisk

Novo Nordisk meets upgraded guidance, setting new revenue record

Further reading

EU Commission to give more time for MDR transition

Orifarm brings in communications lead from Leo Pharma

Extensive layoffs at Leo Pharma – 300 jobs lost

Latest news

Jobs

Jobs